- Home
- GRI
GRI
GRI Bio Inc.
as 12-18-2024 2:37pm EST
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 6.1M | IPO Year: | N/A |
| Target Price: | $11.50 | AVG Volume (30 days): | 384.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $65.00 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GRI Bio Inc. News
GRI Breaking Stock News: Dive into GRI Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
GRI Bio to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire
a month ago
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
GlobeNewswire
a month ago
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
GlobeNewswire
2 months ago
GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024
GlobeNewswire
2 months ago
GRI Bio Announces Exercise of Warrants
GlobeNewswire
2 months ago
GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
GlobeNewswire
2 months ago
GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis
GlobeNewswire
3 months ago
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions
Compare GRI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRI GRI Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.